Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation

[1]  G. Lip,et al.  Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial. , 2016, International journal of cardiology.

[2]  D. Lane,et al.  Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.

[3]  G. Lip,et al.  Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project , 2016, Scientific Reports.

[4]  L. Fauchier,et al.  Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. , 2016, International journal of cardiology.

[5]  G. Lip,et al.  Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. , 2016, The American journal of medicine.

[6]  G. Lip,et al.  Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores , 2016, Scientific Reports.

[7]  D. Lane,et al.  The 5-factor ORBIT bleeding score predicted major bleeding at 2 years in patients with atrial fibrillation , 2016, Annals of Internal Medicine.

[8]  G. Lip,et al.  Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. , 2015, European heart journal.

[9]  Emily C. O'Brien,et al.  The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation , 2015, European heart journal.

[10]  G. Lip,et al.  Assessing Bleeding Risk With the HAS‐BLED Score: Balancing Simplicity, Practicality, and Predictive Value in Bleeding‐Risk Assessment , 2015, Clinical cardiology.

[11]  K. Hong,et al.  The HAS‐BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta‐analysis , 2015, Clinical cardiology.

[12]  D. Singer,et al.  Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. , 2015, American heart journal.

[13]  Á. Cequier,et al.  Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists , 2015, Thrombosis and Haemostasis.

[14]  F. Marín,et al.  The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists , 2015, Thrombosis and Haemostasis.

[15]  S. Raposeiras-Roubín,et al.  Comparative evaluation of HAS-BLED and ATRIA scores by investigating the full potential of their bleeding prediction schemes in non-valvular atrial fibrillation patients on vitamin-K antagonists. , 2014, International journal of cardiology.

[16]  R. Fernandes,et al.  Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis , 2014, Journal of Interventional Cardiac Electrophysiology.

[17]  G. Lip,et al.  Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. , 2013, Chest.

[18]  G. Lip,et al.  Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation , 2013, Thrombosis and Haemostasis.

[19]  R. de Caterina,et al.  Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) , 2013, Thrombosis and Haemostasis.

[20]  G. Lip,et al.  Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. , 2013, Journal of the American College of Cardiology.

[21]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[22]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[23]  A. Banerjee,et al.  Assessing the Risk of Bleeding in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project , 2012, Circulation. Arrhythmia and electrophysiology.

[24]  Yutao Guo,et al.  Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. , 2012, Journal of the American College of Cardiology.

[25]  G. Lip,et al.  Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation , 2012, Circulation. Arrhythmia and electrophysiology.

[26]  J. Plumb,et al.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[27]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[28]  J. Finsterer,et al.  Letter by Stöllberger et al regarding article, "Stroke risk and antithrombotic strategies in atrial fibrillation". , 2011, Stroke.

[29]  G. Hankey,et al.  Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation , 2010, Stroke.

[30]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[31]  R. Perera,et al.  Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review , 2008, Circulation. Cardiovascular quality and outcomes.

[32]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[33]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[34]  Gregory W Albers,et al.  Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. , 2007, Archives of internal medicine.

[35]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[37]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[38]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[39]  Isac C. Thomas,et al.  Bleeding Risk Prediction Models in Atrial Fibrillation , 2013, Current Cardiology Reports.

[40]  G. Lip,et al.  Vitamin K antagonists in heart disease: Current status and perspectives (Section III) , 2013, Thrombosis and Haemostasis.

[41]  G. Lip,et al.  Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. , 2013, Chest.

[42]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[43]  E. Elkin,et al.  Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers , 2008, BMC Medical Informatics Decis. Mak..

[44]  G. Lip,et al.  Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT 2 R 2 Score , 2022 .